Hostname: page-component-848d4c4894-pjpqr Total loading time: 0 Render date: 2024-06-23T01:42:46.758Z Has data issue: false hasContentIssue false

OCD: Perspectives on the Next Millennium From the Adult OCD Research Unit, NIMH Intramural Research Program

Published online by Cambridge University Press:  07 November 2014


Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Supplement Monograph
Copyright © Cambridge University Press 1998

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)



1.Greenberg, BD, George, MS, Benjamin, J, et al.Effect of prefrontal repetitive transcranial magnetic stimulation in obsessive-compulsive disorder: a preliminary study. Am J Psychiatry. 1997;154:867869.Google ScholarPubMed
2.Corá-Locatelli, G, Greenberg, BD, Martin, JD, Murphy, DL. Valproate monotherapy in SRI-intolerant OCD patient. Clin Psychiatry. 1998;59:82.CrossRefGoogle ScholarPubMed
3.Corá-Locatelli, G, Greenberg, BD, Martin, JD, Murphy, DL. Rebound psychiatric and physical symptoms after gabapentin discontinuation. J Clin Psychiatry. In press.Google Scholar
4.Corá-Locatelli, G, Greenberg, BD, Martin, J, Leong, Y-M, Murphy, DL. Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder Submitted.Google Scholar
5.Broocks, A, Pigott, TA, Hill, JL, et al.Acute administration of ondansetron and m-cpp, alone and in combination, in patients with obsessive-compulsive disorder (OCD) and controls: behavioral and biological results. Psychiatry Research. In press.Google Scholar
6.Broocks, A, Briggs, NC, Pigott, TA, et al.Behavioral, physiological, and neuroendocrine responses in healthy volunteers to m-chlorophenylpiperazine (m-CPP) with and without ondansetron pretreatment. Psychopharmacology. 1997;130:91103.CrossRefGoogle ScholarPubMed
7.Altemus, M, Glowa, JR, Galliven, E, Leong, YM, Murphy, DL. Effects of serotonergic agents on food-restriction-induced hyperactivity. Pharmacol Biochem Behav. 1996;53:123131.CrossRefGoogle ScholarPubMed
8.Altemus, M, Murphy, DL. Animal models of obsessive-compulsive disorder. In: Westenberg, HGM, Murphy, DL, Den Boer, JA, eds. Advances in the Neurobiology of Anxiety Disorder. New York: Wiley, 1996:249278.Google Scholar
9.Bengel, D, Murphy, DL, Andrews, AM, et al.Altered brain serotonin (5-HT) homeostasis and locomotor insensitivity to MDMA (“ecstasy”) in 5-HT transporter-deficient mice. Molecular Pharm. 1998;53:649655.CrossRefGoogle ScholarPubMed
10.Murphy, DL, Greenberg, B, Altemus, M, Benjamin, J, Grady, T, Pigott, T. The neuropharmacology and neurobiology of obsessive-compulsive disorder: an update on the serotonin hypothesis. In: Westenberg, HGM, Murphy, DL, Den Boer, JA, eds. Advances in Neurobiology of Anxiety. 1996;2:279298.Google Scholar
11.Murphy, DL, Andrews, AM, Wichems, CH, Li, Q, Greenberg, B. Brain serotonin neurotransmission: an overview and update with an emphasis on serotonin subsystem heterogeneity, multiple receptors interactions with other neurotransmitter systems, and consequent implications for understanding the actions of serotonergic drugs. J Clin Psychiatry. In press.Google Scholar
12.Weiger, WA. Serotonergic modulation of behaviour: a phylogenetic overview. Biol Rev. 1996;72:6195.CrossRefGoogle Scholar
13.Karayiorgou, M, Altemus, M, Galke, BL, et al.Genotype determining low catechol-o-methyltransferase activity as a risk factor for obsessive-compulsive disorder. Proc Natl Acad Sci USA. 1997;94:45724575.Google Scholar